Results 221 to 230 of about 5,361,118 (283)
Novel non-viral in vivo CAR-T therapies: latest updates from the 2025 ASH annual meeting. [PDF]
Xue B, Liu Y, Liang A, Zhang W.
europepmc +1 more source
ABSTRACT Objective In multiple sclerosis, the optimal time for deploying a therapeutic intervention is before the central nervous system is damaged; given the success of trials treating the earliest stage of MS, the radiologically isolated syndrome, developing primary prevention strategies is an important next challenge.
Amy W. Laitinen +7 more
wiley +1 more source
Invisible burdens of platform work: a qualitative study of food-delivery riders' lived experiences in urban India. [PDF]
Kariveliparambil A +4 more
europepmc +1 more source
Epigenetic reprogramming in hematopoietic stem and progenitor cells (HSPCs) and downstream myeloid cells, mediated by H3.3 downregulation and endogenous retroelement (ERE) overexpression, contributes to the progression of multiple sclerosis (MS). ABSTRACT Background Skewed myelopoiesis in the bone marrow has been identified as a key driver of multiple ...
Li‐Mei Xiao +6 more
wiley +1 more source
Configurational Setup for Fully Robotic Distal Pancreatectomy with Splenectomy Using Hugo™ RAS and Ligasure™ RAS Maryland: First Case Report (With Video). [PDF]
Belyaev O, Salama H, Fahlbusch T, Uhl W.
europepmc +1 more source
Location‐Specific Hematoma Volume Predicts Early Neurological Deterioration in Supratentorial ICH
ABSTRACT Objective Early neurological deterioration (END) adversely affects outcomes in patients with intracerebral hemorrhage (ICH). This study aimed to determine the location‐specific hematoma volumes for END in supratentorial ICH patients. Methods We retrospectively analyzed supratentorial ICH patients presenting from two prospective cohorts.
Zuoqiao Li +10 more
wiley +1 more source
Platform trial of smartphone-based cognitive-behavioural therapy (CBT) for depressive symptoms among people with no or subthreshold depression: a protocol for the Best, Efficient and Affordable Training in Resilience in Constant Evolution (BEATRICE) platform trial. [PDF]
Furukawa TA +20 more
europepmc +1 more source

